Biologics, such as monoclonal antibodies, therapeutic proteins, gene therapies, and vaccines, are revolutionizing treatments for cancer, autoimmune disorders, and infectious diseases. However, their inherent sensitivity to environmental factors like heat and moisture necessitates advanced stabilization techniques. Lyophilization, or freeze-drying, has emerged as a critical method to preserve biologics by removing water through sublimation, resulting in a stable, dry powder. This review examines recent advancements in lyophilization, including the integration of Quality by Design (QbD) and Process Analytical Techniques (PAT), which enhance process optimization and product consistency. Regulatory frameworks from the FDA and EMA, coupled with advanced analytical methods, ensure the safety and efficacy of lyophilized biologics. The review also explores emerging technologies and innovations poised to address current challenges, such as scalability, cost-efficiency, and long-term stability. By synthesizing scientific, technological, and regulatory perspectives, this article provides a comprehensive overview of lyophilization's role in biopharmaceutical development and its future potential to meet the growing demands of biologic therapeutics.
Khatoon et al. (2026) studied this question.